Back to 
NATIXIS
NATIXIS
BCTXShowing 0 of 4 quarters
Position history for NATIXIS's holdings in BRIACELL THERAPEUTICS CORP
No. Natixis exited its BCTX (Briacell Therapeutics) position in Q3 2023. Its Q2 2023 13F listed 90,250 shares worth $579,405. Natixis first reported BCTX in Q4 2022 and held it in 2 quarterly 13F filings.
Current Value
-
Current Shares
-
Total Value Change
$0
Total Shares Change
0
No position history available for this security.
Other major holders of BCTX: WASATCH ADVISORS LP, Hudson Bay Capital Management LP